Ibrutinib vs chlorambucil in CLL patients not suitable for chemotherapy
A novel WINDOW of opportunity for young mantle cell lymphoma patients
Treating indolent and mantle cell lymphoma: results of the BRIGHT 5 year follow up study
What are the advantages of multiple myeloma maintenance therapy?
Potential second-line treatment for indolent lymphoma